Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Confident With Legacy Innovation In Japan And Emerging Markets - JP Morgan Healthcare Conference

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Merck has been quite vocal in recent months about shifting its focus to emerging markets, but the company is also expecting big gains in Japan due to a slate of upcoming market launches

You may also be interested in...



Merck, Cipla Deny Deal Talks But The Charm Of The Indian Market Stokes Speculations

MUMBAI - Merck CEO designate Kenneth Frazier's visit to India accompanied by key global leaders earlier this month sparked rumors that takeover of a large Indian company could be on Merck's wish list and Cipla - the largest home-grown company by market share - may be the likely target on the Big Pharma's radar

Merck Powering Up In Emerging Markets Through Alliance And Pricing Strategies

As Merck looks to expand its geographic footprint in emerging markets, local players with extensive distribution networks will be the focus for partnerships, Merck Chief Strategy Officer and former Emerging Markets R&D Head Mervyn Turner told investors at the CLSA Emerging Markets Pharma Conference Dec.1 in New York

Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 1 of 2)

NEW YORK - Emerging markets will account for almost half of the global pharmaceutical market growth through 2014, according to IMS Health VP Rob Arnold

Related Content

Latest News
UsernamePublicRestriction

Register

SC076156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel